Question special
Resident

Dear Dr. Trivedi and co-authors, thank you for this excellent scientific investigation, it was a great pleasure to read! My question pertains to the participants in Stage 1 that were randomized to receive buproprion-naltrexone. Following the 6 weeks of Stage 1, did they continue to receive the medication or was it stopped? If it was stopped, did the authors have the chance to collect any data at week 12 to assess medium-term effects of the drug on methamphetamine use disorder?